About us
Measure to understand, understand to formulate
BioRegenis is a biotech start-up developing health and wellbeing technologies, pharmaceutical and otherwise, with artificial intelligence and data science built into the research process.
At the centre of the work sits the development and use of biomarkers: measure to understand, understand to formulate.
The company was founded with an international outlook and an orientation towards expansion across several markets.
The goal is to cover the entire chain: biochips for individual analysis, use of that data to build targeted products, and specific products that sustain the balance of body and mind over time.
01
How we work
The method comes from more than thirty years of the team's research experience, reorganised into a repeatable process.
The method comes from more than thirty years of the team's research experience, reorganised into a repeatable process.
It starts from computational analysis and proceeds in successive stages: study of molecules and their combinations, receptor areas and mechanisms of action, ADME, toxicology, development of the final product and the regulatory path through to market entry.
Exit criteria
It hands it back multiplied further down the line.
Every stage has defined exit criteria, and none is declared closed before it has answered the question it exists for. A stage closed quickly but badly saves no time.
That is why the feasibility assessment comes before development rather than after: if an idea has no viable route to market, it is better to know while it is still cheap.
The same criterion governs what we publish. A programme appears on this site once its intellectual property position is protected, not when announcing it would be convenient.
The competences
The team was formed mainly in cosmetics, medical devices and supplements — sectors where the development cycle is short, the regulatory constraint tight and market feedback immediate. That is where the competence we now also apply to pharmaceuticals came from: computational tools and decision algorithms that act in the early stages of research, where most of the cost of mistakes is concentrated.
On that base sit established competences in regulatory affairs, pharmacovigilance and formulation development, which let us assess from the outset whether an idea has a viable route to market.
- 6
- Published programmes
- 30+
- Years of team research
- 44%
- Average maturity
- Italy
- Based in
The team
Research, formulation development, regulatory affairs and communication, held together by in-house scientific direction.
Antonio Mazzucco
CEO
An expert in nutraceuticals, cosmetics, medical devices and pharmaceuticals, internationally recognised for his work. He applies data science to speed up decision-making from research and development onwards, robotic automation and personalised products.
Elio Carrea
Natalia Romanova
Marketing and digital communication
An expert in marketing and digital communication, with strong international experience.
Where we stand
The pipeline shows the real state of each programme, with its next milestone.
Go to the pipeline